Indegene listed among Asia-Pacific's high-growth firms by FT

** Indegene (BSE: 544172, NSE: INDGN) announced today its inclusion in the Financial Times' list of High-Growth Companies in Asia-Pacific 2025, marking its second year in a row on the prestigious list. The recognition highlights companies in the region demonstrating substantial revenue growth, particularly those leveraging technology or innovative business models. Indegene combines healthcare expertise with a digital-first approach to assist biopharma and medical device companies in commercializing their products. The company's client base includes top 20 global biopharma firms. With approximately 5,000 employees worldwide, Indegene operates six operation hubs and maintains 18 offices across North America, Europe, and Asia. The company aims to enable healthcare organizations to be future-ready, offering solutions that provide personalized experiences for patients and physicians.